Skip to main content
SpringerLink
Log in
Book cover

Advances and Technical Standards in Neurosurgery pp 91–108Cite as

Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas

  • Chapter

Part of the book series: Advances and Technical Standards in Neurosurgery ((NEUROSURGERY,volume 43))

Abstract

Sorting and grading of glial tumors by the WHO classification provide clinicians with guidance as to the predicted course of the disease and choice of treatment. Nonetheless, histologically identical tumors may have very different outcome and response to treatment. Molecular markers that carry both diagnostic and prognostic information add useful tools to traditional classification by redefining tumor subtypes within each WHO category. Therefore, molecular markers have become an integral part of tumor assessment in modern neuro-oncology and biomarker status now guides clinical decisions in some subtypes of gliomas. The routine assessment of IDH status improves histological diagnostic accuracy by differentiating diffuse glioma from reactive gliosis. It carries a favorable prognostic implication for all glial tumors and it is predictive for chemotherapeutic response in anaplastic oligodendrogliomas with codeletion of 1p/19q chromosomes. Glial tumors that contain chromosomal codeletion of 1p/19q are defined as tumors of oligodendroglial lineage and have favorable prognosis. MGMT promoter methylation is a favorable prognostic marker in astrocytic high-grade gliomas and it is predictive for chemotherapeutic response in anaplastic gliomas with wild-type IDH1/2 and in glioblastoma of the elderly. The clinical implication of other molecular markers of gliomas like mutations of EGFR and ATRX genes and BRAF fusion or point mutation is highlighted. The potential of molecular biomarker-based classification to guide future therapeutic approach is discussed and accentuated.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Abedalthagafi M, Phillips JJ, Kim GE, Mueller S, Haas-Kogen DA, Marshall RE et al (2013) The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. Mod Pathol Off J U S A Can Acad Pathol Inc 26:1425–1432

    CAS  Google Scholar 

  2. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A et al (2008) Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10:619–624

    Article  CAS  PubMed  Google Scholar 

  3. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F et al (2011) IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224:334–343

    Article  CAS  PubMed  Google Scholar 

  4. Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP et al (2013) Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest 123:3659–3663

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Babu R, Adamson DC (2012) Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid 7:93–103

    PubMed Central  CAS  PubMed  Google Scholar 

  6. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M et al (2014) IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16:81–91

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Bertolino N, Marchionni C, Ghielmetti F, Burns B, Finocchiaro G, Anghileri E et al (2014) Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: a phantom study. Phys Med PM Int J Devot Appl Phys Med Biol Off J Ital Assoc Biomed Phys 30:702–707

    Google Scholar 

  8. Bolduc JM, Dyer DH, Scott WG, Singer P, Sweet RM, Koshland DE Jr et al (1995) Mutagenesis and Laue structures of enzyme intermediates: isocitrate dehydrogenase. Science 268:1312–1318

    Article  CAS  PubMed  Google Scholar 

  9. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS et al (2012) Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 17:72–79

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol Off J Am Soc Clin Oncol 26:2192–2197

    Article  Google Scholar 

  11. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol Off J Am Soc Clin Oncol 31:337–343

    Article  CAS  Google Scholar 

  12. Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG et al (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol Off J Am Soc Clin Oncol 32:783–790

    Article  CAS  Google Scholar 

  13. Cankovic M, Nikiforova MN, Snuderl M, Adesina AM, Lindeman N, Wen PY et al (2013) The role of MGMT testing in clinical practice: a report of the association for molecular pathology. J Mol Diagn JMD 15:539–555

    Article  CAS  PubMed  Google Scholar 

  14. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245–254

    Article  CAS  PubMed  Google Scholar 

  15. Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M et al (2012) Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One 7:e33449

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Clynes D, Jelinska C, Xella B, Ayyub H, Taylor S, Mitson M et al (2014) ATRX dysfunction induces replication defects in primary mouse cells. PLoS One 9:e92915

    Article  PubMed Central  PubMed  Google Scholar 

  17. Dahiya S, Emnett RJ, Haydon DH, Leonard JR, Phillips JJ, Perry A et al (2014) BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol 16:318–319

    Article  PubMed Central  PubMed  Google Scholar 

  18. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Ellingson BM, Cloughesy TF, Pope WB, Zaw TM, Phillips H, Lalezari S et al (2012) Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage 59:908–916

    Article  CAS  PubMed  Google Scholar 

  20. Faulkner C, Palmer A, Williams H, Wragg C, Haynes HR, White P et al (2014) EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers. Br J Neurosurg 1–7

    Google Scholar 

  21. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M et al (2011) Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer J Int du Cancer 129:659–670

    Article  CAS  Google Scholar 

  22. Fiano V, Trevisan M, Trevisan E, Senetta R, Castiglione A, Sacerdote C et al (2014) MGMT promoter methylation in plasma of glioma patients receiving temozolomide. J Neurooncol 117:347–357

    Article  CAS  PubMed  Google Scholar 

  23. Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW et al (2009) Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 218:172–181

    Article  CAS  PubMed  Google Scholar 

  24. Freidlin B, McShane LM, Korn EL (2010) Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 102:152–160

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Freidlin B, Sun Z, Gray R, Korn EL (2013) Phase III clinical trials that integrate treatment and biomarker evaluation. J Clin Oncol Off J Am Soc Clin Oncol 31:3158–3161

    Article  CAS  Google Scholar 

  26. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol Off J Am Soc Clin Oncol 31:4085–4091

    Article  CAS  Google Scholar 

  27. Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K, Felsberg J et al (2007) Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer J Int du Cancer 121:2458–2464

    Article  CAS  Google Scholar 

  28. Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C et al (2011) Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res Off J Am Assoc Cancer Res 17:4588–4599

    Article  CAS  Google Scholar 

  29. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718

    Article  PubMed  Google Scholar 

  30. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474

    Article  PubMed  Google Scholar 

  31. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

    Article  CAS  PubMed  Google Scholar 

  32. Ho VK, Reijneveld JC, Enting RH, Bienfait HP, Robe P, Baumert BG et al (2014) Changing incidence and improved survival of gliomas. Eur J Cancer 50:2309–2318

    Article  PubMed  Google Scholar 

  33. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M et al (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861

    Article  CAS  PubMed  Google Scholar 

  34. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722

    Article  PubMed Central  PubMed  Google Scholar 

  35. Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S et al (2010) Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 97:311–322

    Article  CAS  PubMed  Google Scholar 

  36. Kieran MW (2014) Targeting BRAF in pediatric brain tumors. Am Soc Clin Oncol Educ Book/ASCO. Am Soc Clin Oncol. Meeting. e436–e440. PMID: 24857135

    Google Scholar 

  37. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H et al (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118:401–405

    Article  CAS  PubMed  Google Scholar 

  38. Krell D, Mulholland P, Frampton AE, Krell J, Stebbing J, Bardella C (2013) IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncol 9:1923–1935

    Article  CAS  PubMed  Google Scholar 

  39. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F et al (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol Off J Am Soc Clin Oncol 29:4482–4490

    Article  CAS  Google Scholar 

  40. Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T (2010) Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro Oncol 12:173–180

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Levner I, Drabycz S, Roldan G, De Robles P, Cairncross JG, Mitchell R (2009) Predicting MGMT methylation status of glioblastomas from MRI texture. Med Image Comput Computer Assist Interv MICCAI … Int Conf Med Image Comput Comput Assist Interv 12:522–530

    Google Scholar 

  42. Liu L, Backlund LM, Nilsson BR, Grander D, Ichimura K, Goike HM et al (2005) Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 83:917–926

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso AM et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615–625

    Article  CAS  PubMed  Google Scholar 

  44. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926

    Article  PubMed  Google Scholar 

  45. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058–1066

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D et al (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719–729

    Article  PubMed  Google Scholar 

  47. Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JW, Boots-Sprenger SH et al (2014) The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol 16:1263–1273

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ (1996) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56:5079–5086

    CAS  PubMed  Google Scholar 

  49. NCCN (2013) Clinical practice guidelines in oncology. Central nervous system cancers, Version 2. http://www.nccn.org

  50. Nikiforova MN, Hamilton RL (2011) Molecular diagnostics of gliomas. Arch Pathol Lab Med 135:558–568

    CAS  PubMed  Google Scholar 

  51. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510–522

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Park CK, Kim J, Yim SY, Lee AR, Han JH, Kim CY et al (2011) Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. Neuro Oncol 13:195–202

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Pegg AE (2000) Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 462:83–100

    Article  CAS  PubMed  Google Scholar 

  55. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P et al (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol Off J Am Soc Clin Oncol 20:2076–2084

    Article  Google Scholar 

  56. Popovici-Muller J, Saunders JO, Salituro FG, Travins JM, Yan S, Zhao F et al (2012) Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med Chem Lett 3:850–855

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. Quillien V, Lavenu A, Sanson M, Legrain M, Dubus P, Karayan-Tapon L et al (2014) Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients. J Neurooncol 116:487–496

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175–1190

    PubMed Central  CAS  PubMed  Google Scholar 

  59. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C et al (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340:626–630

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Romano A, Calabria LF, Tavanti F, Minniti G, Rossi-Espagnet MC, Coppola V et al (2013) Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status. Eur Radiol 23:513–520

    Article  PubMed  Google Scholar 

  61. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231

    Article  CAS  PubMed  Google Scholar 

  62. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV et al (2010) Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 70:8981–8987

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Shao H, Chung J, Balaj L, Charest A, Bigner DD, Carter BS et al (2012) Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med 18:1835–1840

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  64. Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446–1452

    Article  PubMed Central  PubMed  Google Scholar 

  65. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  CAS  PubMed  Google Scholar 

  66. Suzuki MM, Bird A (2008) DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 9:465–476

    Article  CAS  PubMed  Google Scholar 

  67. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E et al (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479–483

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  68. Uhlmann K, Rohde K, Zeller C, Szymas J, Vogel S, Marczinek K et al (2003) Distinct methylation profiles of glioma subtypes. Int J Cancer J Int du Cancer 106:52–59

    Article  CAS  Google Scholar 

  69. van den Bent MJ, Hartmann C, Preusser M, Strobel T, Dubbink HJ, Kros JM et al (2013) Interlaboratory comparison of IDH mutation detection. J Neurooncol 112:173–178

    Article  PubMed  Google Scholar 

  70. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P et al (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res Off J Am Assoc Cancer Res 16:1597–1604

    Article  Google Scholar 

  71. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol Off J Am Soc Clin Oncol 31:344–350

    Article  Google Scholar 

  72. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E et al (2013) Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340:622–626

    Article  CAS  PubMed  Google Scholar 

  74. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Weiler M, Wick W (2012) Molecular predictors of outcome in low-grade glioma. Curr Opin Neurol 25:767–773

    Article  PubMed  Google Scholar 

  76. Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R (2013) Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 14:e370–e379

    Article  CAS  PubMed  Google Scholar 

  77. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715

    Article  CAS  PubMed  Google Scholar 

  78. Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B et al (2013) Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 81:1515–1522

    Article  CAS  PubMed  Google Scholar 

  79. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol Off J Am Soc Clin Oncol 27:5874–5880

    Article  CAS  Google Scholar 

  80. Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451

    Article  CAS  PubMed  Google Scholar 

  81. Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T et al (2013) Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol 15:1017–1026

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  82. Wiestler B, Capper D, Sill M, Jones DT, Hovestadt V, Sturm D et al (2014) Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol

    Google Scholar 

  83. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH et al (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  84. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Neuro-Oncology, Davidoff Institute of Oncology, Rabin Medical Center, Campus Beilinson, Petach Tikva, 49100, Israel

    Tali Siegal MD

Authors
  1. Tali Siegal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tali Siegal MD .

Editor information

Editors and Affiliations

  1. Medical Faculty, Universtiy of Bonn, Bonn, Germany

    Johannes Schramm

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Siegal, T. (2016). Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas. In: Schramm, J. (eds) Advances and Technical Standards in Neurosurgery. Advances and Technical Standards in Neurosurgery, vol 43. Springer, Cham. https://doi.org/10.1007/978-3-319-21359-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-21359-0_4

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-21358-3

  • Online ISBN: 978-3-319-21359-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation